Oral drug delivery company IntelGenx said Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for tadalafil film product under erectile dysfunction (ED) dosing patent US Patent No. 6,943,166.
Any exclusivity associated with the tadalafil compound patent expiring is not affected by this agreement.
“Obtaining exclusivity for our Tadalafil VersaFilm product is a significant achievement for IntelGenx,” said IntelGenx CEO Horst Zerbe.
“With this exclusive license, IntelGenx has the opportunity to be the first and only Tadalafil film product on the U.S. ED market while the ‘166 dosing patent remains in force.
“Exclusive access to Lilly’s dosing patent will further accelerate our partnering activities while potentially securing our early entry into the lucrative U.S. ED market.”
IntelGenx said subject to US Food and Drug Administration (FDA) approval, this exclusive license allows IntelGenx to commercialize its Tadalafil ED VersaFilm product in the US prior to the expiration of the ‘166 dosing patent.
“With this license, IntelGenx is the only company that has a free and clear pathway to launch a tadalafil film product for the treatment of ED in the US,” said IntelGenx.
IntelGenx was represented by H. Keeto Sabharwal and the law firm of Pillsbury Winthrop Shaw Pittman.